Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Enveric Biosciences, Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

Enveric Biosciences, Inc.

ENVBNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026.…

Filed Jun 9, 2026Accepted Jun 8, 2026, 5:53 PM EDTCIK 890821Accession 0001493152-26-027781
View company →Permanent SEC source ↗
Share

Company context

We are a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, we are advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Our lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.

Current securities

ENVBNASDAQ · EQUITY · Current
Historical securities (1)
AMRHWNASDAQ · WARRANT · Historical · closed Dec 31, 2020

Recent company filings

  1. 10-Q filingAug 14, 2026
  2. Results of Operations and Financial ConditionAug 14, 2026
  3. SCHEDULE 13G/A filingAug 14, 2026
  4. SCHEDULE 13G filingAug 14, 2026
  5. SCHEDULE 13G/A filingAug 13, 2026

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026. From time to time thereafter, the Company may use the Investor Presentation, possibly with modifications, in presentations to current and potential investors, analysts, lenders, business partners, acquisition candidates, customers, employees, and others with an interest in the Company and its business. A copy of the Investor Presentation is furnished as Exhibit 99.1 to this report and incorporated here by reference. A copy of the Investor Presentation is also available via the Company’s website at https://www.enveric.com/investors/events/. Materials on the Company’s website are not part of or incorporated by reference into this report. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)